Cardiovascular and renal benefits of novel diabetes drugs by baseline cardiovascular risk: a systematic review, meta-analysis, and meta-regression
JM Rodriguez-Valadez, M Tahsin… - Diabetes …, 2023 - Am Diabetes Assoc
BACKGROUND Eligibility for glucagon-like peptide 1 receptor agonists (GLP-1RA) and
sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with …
sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with …
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
M Lugner, N Sattar, M Miftaraj, J Ekelund… - Cardiovascular …, 2021 - Springer
Background Major prospective randomized clinical safety trials have demonstrated
beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and …
beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and …
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta …
Background Recent large clinical trials have demonstrated cardiovascular benefits of similar
overall magnitude for sodium–glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like …
overall magnitude for sodium–glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like …
Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and …
TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich… - Circulation, 2019 - Am Heart Assoc
Background: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose
cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic …
cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic …
Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy
Background: Several glucagon-like peptide receptor agonists (GLP-1RA) and sodium-
glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefit in …
glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefit in …
Potential mediators for treatment effects of novel diabetes medications on cardiovascular and renal outcomes: a meta‐regression analysis
JM Rodriguez‐Valadez, M Tahsin… - Journal of the …, 2024 - Am Heart Assoc
Background Prior research suggests clinical effects of glucagon‐like peptide‐1 receptor
agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are …
agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are …
Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real …
I Caruso, A Cignarelli, GP Sorice, A Natalicchio… - Metabolites, 2022 - mdpi.com
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Background Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1
RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular …
RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular …
The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta …
MU Ali, GBJ Mancini, D Fitzpatrick-Lewis… - Canadian Journal of …, 2022 - Elsevier
Background Evidence for the cardiorenal risk reduction properties of antihyperglycemic
medications originally prescribed for type 2 diabetes, sodium-glucose cotransporter 2 …
medications originally prescribed for type 2 diabetes, sodium-glucose cotransporter 2 …
Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta …
XB Wei, W Wei, LL Ding, SY Liu - Primary care diabetes, 2021 - Elsevier
The relative efficacy of different sodium glucose cotransporter 2 (SGLT2) inhibitors and
glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in reducing cardiorenal events in …
glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in reducing cardiorenal events in …
相关搜索
- receptor agonists meta analysis
- sodium glucose meta analysis
- diabetes drugs meta regression
- cardiovascular efficacy meta analysis
- drug classes meta analysis
- diabetes mellitus meta analysis
- treatment effects meta regression
- drug classes cardiovascular outcomes
- cardiorenal outcomes meta analysis
- diabetes drugs meta analysis
- cardiovascular outcomes meta analysis
- diabetes medications meta regression
- inhibitors and glucagon meta analysis